Executing A Product Pivot With Vir Bio's Mark Eisner, MD Business Of Biotech podcast

Content provided by Ben Comer. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Ben Comer or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

Business Of Biotech »
Executing A Product Pivot With Vir Bio's Mark Eisner, MD

3d ago 39:45

MP3•Episode home

We love to hear from our listeners. Send us a message.

On this week's episode of the Business of Biotech, Dr. Mark Eisner, EVP and Chief Medical Officer at Vir Bio, talks about the company's post-COVID pivot into infectious diseases (Hepatitis Delta and Hepatitis B) and oncology (solid tumors), how he reprioritized the company's development candidates and assimilated Sanofi's acquired T cell engager platform, and his own transition from healthcare provider to clinical research.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Chapters

1. Introduction and Career Journey (00:00:00)

2. Vir's Strategic Reorganization (00:09:53)

3. Building Teams and Leading Change (00:17:15)

4. Innovative Technology Platforms (00:22:35)

5. Hepatitis Delta: A Devastating Disease (00:29:31)

6. Oncology Programs and T-cell Engagers (00:34:17)

254 episodes

#Science #MBA #Biology #Business #Matt Pillar #Biopharmaceutical #Bioprocess #Biopharma #Medicine #Therapy #Startup #Venturecapital #Entrepreneur #Pharma #Biotech